Spinal cord injury (SCI) commonly results in the development of neuropathic pain, which can dramatically impair the quality of life for SCI patients. SCI-induced neuropathic pain can be manifested as both tactile allodynia (a painful sensation to a non-noxious stimulus) and hyperalgesia (an enhanced sensation to a painful stimulus). The mechanisms underlying these pain states are poorly understood. Clinical studies have shown that gabapentin, a drug that binds to the voltage-gated calcium channel alpha-2-delta-1 subunit (Ca v a2d-1) proteins is effective in the management of SCI-induced neuropathic pain. Accordingly, we hypothesized that tactile allodynia post SCI is mediated by an upregulation of Ca v a2d-1 in dorsal spinal cord. To test this hypothesis, we examined whether SCI-induced dysregulation of spinal Ca v a2d-1 plays a contributory role in below-level allodynia development in a rat spinal T9 contusion injury model. We found that Ca v a2d-1 expression levels were significantly increased in L4-6 dorsal, but not ventral, spinal cord of SCI rats that correlated with tactile allodynia development in the hind paw plantar surface. Furthermore, both intrathecal gabapentin treatment and blocking SCI-induced Ca v a2d-1 protein upregulation by intrathecal Ca v a2d-1 antisense oligodeoxynucleotides could reverse tactile allodynia in SCI rats. These findings support that SCI-induced Ca v a2d-1 upregulation in spinal dorsal horn is a key component in mediating below-level neuropathic pain states, and selectively targeting this pathway may provide effective pain relief for SCI patients. Ó
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Introduction
Approximately 1,275,000 individuals in the United States suffer from paralysis due to spinal cord injuries (SCI), with 11,000 cases occurring each year [37, 44] . Although the primary effect of SCI is the loss of motor functions, the development of neuropathic pain, or pain derived from injuries to the nervous systems, is a common consequence prevalent in more than half of individuals with SCI [43] . Neuropathic pain can be manifested in some SCI patients as a painful sensation evoked by a non-noxious stimulus (tactile allodynia) or exaggerated pain sensations to mild painful stimuli (hyperalgesia). Retrospective clinical studies have shown that 65% of SCI patients suffer from pain that interferences with activities of their daily lives, and 60% of those patients use medications for pain management [10, 34] . Unfortunately, current pain medications are only partially effective and associated with unwanted side effects. This lack of effective and safe pharmacological agents for alleviation of SCI pain is mainly due to our insufficient knowledge in understanding the mechanisms underlying SCI-induced neuropathic pain.
Previous findings have demonstrated that peripheral nerve injury induces upregulation of the voltage gated calcium channel (VGCC) alpha-2-delta-1 (Ca v a2d-1) subunit protein in dorsal spinal cord (DSC) that contributes to the development of tactile allodynia [29] . The Ca v a2d-1 protein is a highly glycosylated extracellular subunit associated with VGCC. The Ca v a2d-1 plays an important role for functional assembly of the VGCC in the cell membrane [2, 12, 15, 24] . In addition, studies have shown that upregulated Ca v a2d-1 subunit modulates calcium channel current density and synaptogenesis [9, 14, 30] . These factors may contribute to neuropathic pain development. In fact, development of tactile allodynia was either prevented [4] 
